Business
Trading Update & Notice of Capital Markets Event
Animalcare Group Plc reported a strong financial performance for the year ended 31 December 2025, with revenue increasing 20% to approximately £89.1 million, driven by the successful integration of Randlab and growth in flagship brands like Daxocox and its dental portfolio. Underlying EBITDA saw a significant increase of approximately 50% compared to the prior year, with cash conversion in line with guidance at around 80%. The company maintained a strong financial position with net debt at £9.1 million, well below one time underlying EBITDA. Animalcare also advanced its R&D pipeline, with five key projects underway, and plans to invest approximately 5% of revenue annually in innovation from 2026. The company will host a Capital Markets Event on 4 March 2026 to discuss its growth strategy. Disclaimer*
About this update from Animalcare Group Plc
[{"type":"text","content":"\n\n22 January 2026\n \nAnimalcare Group plc\n(\"Animalcare\", the \"Company\", or together with its subsidiaries, the \"Group\")\n \nFY25 Trading Update and Notice of Capital Markets Event\nA year of financial delivery and strong strategic execution provide the foundations for growth acceleration\n \nAnimalcare Group Plc (AIM: ANCR), the international animal health business, provides the following unaudited trading update for the year ended 31 December 2025 (\"FY25\"), delivering strong revenue and underlying EBITDA growth, in line with market expectations1.\n \nHighlights\n \n\n\n\n\n· \n\n\nRevenue up 20% at actual exchange rates (\"AER\") and constant exchange rates (\"CER\") to approximately £89.1m (2024: £74.2m)\n\n\n\n\n· \n\n\nSuccessful integration of Randlab as part of the Group, delivering significant contribution to both revenue and underlying EBITDA growth\n\n\n\n\n· \n\n\nUnderlying EBITDA growth of approximately 50% versus prior year (2024: £11.6m)\n\n\n\n\n· \n\n\nStrong cash conversion in line with FY25 guidance of c. 80% (2024: 103%)\n\n\n\n\n· \n\n\nFinancial position remains strong: net debt at £9.1m as at 31 December 2025 (2024: £9.0m), excluding lease liabilities, with leverage well below 1.0 times underlying EBITDA\n\n\n\n\n· \n\n\nStrengthened R&D pipeline with five key projects in progress, including the VHH NGF antibody programme acquired during the period\n\n\n\n\n \nBusiness and Financial review\n \nStrong revenue growth at higher margins\n \nAnimalcare delivered a positive trading performance in the year, with strong revenue growth, improved margins, and strong cash generation. Revenues grew 20% to £89.1m at AER, which includes organic revenue growth of 2% and the benefit of the successful acquisition and integration of Randlab.\n \nCompanion Animal revenue growth benefited from strong double-digit momentum in the Group's flagship brands, including Daxocox, fueled by the addition of two new tablet strengths to the range. Animalcare's dental portfolio, encompassing Plaqtiv+ and Orozyme, delivered very strong growth, both domestically and within the Group's International Partners (export) network.\n \nProduction Animal revenues returned to more typi...